BDX logo

BDX

Becton Dickinson and Company

$199.51
+$1.11(+0.56%)
52
Overall
95
Value
20
Tech
42
Quality
Market Cap
$53.26B
Volume
996.88K
52W Range
$162.29 - $251.99
Target Price
$200.40

Company Overview

Mkt Cap$53.26BPrice$199.51
Volume996.88KChange+0.56%
P/E Ratio31.2Open$198.74
Revenue$20.2BPrev Close$198.40
Net Income$1.7B52W Range$162.29 - $251.99
Div Yield4.20%Target$200.40
Overall52Value95
Quality42Technical20

No chart data available

About Becton Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Sector: Healthcare
Industry: Medical Instruments & Supplies

Latest News

Abingdon Health PLC Secures Strong Shareholder Support at AGM

An update from Abingdon Health PLC ( ($GB:ABDX) ) is now available. Abingdon Health PLC announced that all resolutions were passed with over 99.7% ...

TipRanks UK Auto-Generated Newsdesk2 days ago

Jefferies Remains a Buy on Becton Dickinson (BDX)

TipRanks Auto-Generated Intelligence Newsdesk2 days ago

BCAL Diagnostics to Launch Nationwide Cancer Detection Tests in Australia

TipRanks Australian Auto-Generated Newsdesk3 days ago

GSH Corporation Secures SGD29 Million Loan with Shareholder Condition

TipRanks Singapore Auto-Generated Newsdesk14 days ago

GSH Corporation Secures CNH 90 Million Loan with Control Conditions

TipRanks Singapore Auto-Generated Newsdesk14 days ago
ABCD
1SymbolPriceChangeVol
2BDX$199.51+0.6%996.88K
3
4
5
6

Get Becton Dickinson and Company Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.